Symptoms and General Pathology

All Conditions

Neoplasms

Digestive System Diseases

Recurrence

Carcinoma

Colorectal Neoplasms

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Intestinal Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Colonic Diseases

Intestinal Diseases

Rectal Diseases

Colorectal cancer patients with advanced or recurrent tumors

Molecular profiling of native tumor will be performed and analyzed by using a self-designed panel. Tumor organoids will be cultured from fresh tumor tissues and patient-derived xenografts model will be established using the tumor organoids. Drugs will be tested in the two models. And the recommendation will be communicated to the clinicians.

Molecular Profiling & drug testing in tumor organoids and PDXs

Zheng Wang, MD/PhD

Luming Xu

Researchers collect specimens from advanced or recurrent colorectal cancer (CRC) patients to conduct molecular profiling and establish tumor organoids (PDOs)/ patient-derived xenografts (PDXs). The aim of this study is to identify clinical actionable targets and predict in vivo response of the tumor to targeted drugs by using PDOs/ PDXs. And the above-mentioned studies will provide the patients with potential personalized cancer treatment options.

Patient-derived organoid is a model that can recapitulate the histology and behavior of the cancer from which it is derived, and is increasingly used as a tool for drug development in pre-clinical settings. Clinical treatment option of colorectal cancer now is quite limited. By molecular profiling, clinical actionable alterations may be identified. And according to the genomic investigation results, we can find the matched targeted drugs, following further testing in the organoids and PDXs. This will provide an opportunity to guide the precision medicine.

Tumour samples will be collected for molecular characterization and organoids establishment.

Molecular Study and Precision Medicine for Colorectal Cancer

Precision Medicine for Advanced or Recurrent Colorectal Cancer Directed by High-throughput Sequencing and Tumor Organoids Model

Viability of organoid is measured using CellTiter-Glo by quantifying ATP, which indicates the presence of metabolically active cells.

Genomic gene mutation numbers are identified using the Next-Generation Sequencing (NGS).

Size of the tumor is measured to reflect the drug response.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Molecular Study and Precision Medicine for Colorectal Cancer	NCT05883683	Advanced Colore... Recurrent Color...	Molecular Profi...	18 Years - 75 Years	Wuhan Union Hospital, China
Molecular Study and Precision Medicine for Colorectal Cancer	NCT05883683	Advanced Colore... Recurrent Color...	Molecular Profi...	18 Years - 75 Years	Wuhan Union Hospital, China

Spots Global Cancer Trial Database for molecular profiling & drug testing in tumor organoids and pdxs